PNC Financial Services Group
AKBA icon

PNC Financial Services Group’s Akebia Therapeutics AKBA Stock Holding History

PNC Financial Services Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$887 Buy
+778
New +$926 ﹤0.01% 4864
2025
Q4 		– Sell
-13
Closed -$35 – 5157
2025
Q3 		$35 Buy
+13
New +$43 ﹤0.01% 5048
2020
Q4 		– Sell
-2,052
Closed -$5K – 3952
2020
Q3 		$5K Hold
2,052
– – ﹤0.01% 3658
2020
Q2 		$28K Buy
+2,052
New +$21.2K ﹤0.01% 3046
2020
Q1 		– Sell
-110
Closed -$1K – 3875
2019
Q4 		$1K Hold
110
– – ﹤0.01% 3863
2019
Q3 		$0 Hold
110
– – ﹤0.01% 3975
2019
Q2 		$1K Hold
110
– – ﹤0.01% 3922
2019
Q1 		$1K Hold
110
– – ﹤0.01% 3926
2018
Q4 		$1K Hold
110
– – ﹤0.01% 3926
2018
Q3 		$1K Hold
110
– – ﹤0.01% 4011
2018
Q2 		$1K Sell
110
-313,786
-100% -$3.14M ﹤0.01% 4038
2018
Q1 		$2.99M Buy
313,896
+313,848
+653,850% +$4.39M ﹤0.01% 896
2017
Q4 		$0 Buy
+48
New +$796 ﹤0.01% 4132

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

PNC Financial Services Group's AKBA Position: Q2 2026 in Review

PNC Financial Services Group opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 778 shares worth $887. The stake represents ﹤0.01% of the portfolio and ranks #4864 among its holdings. This is a return to the name: PNC Financial Services Group previously reported a position in AKBA as recently as Q3 2025.

PNC Financial Services Group first reported a position in AKBA in Q4 2017 and has held it in 13 quarters since. The position peaked at $2.99M in Q1 2018. 60 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • PNC Financial Services Group held 778 shares of Akebia Therapeutics worth $887 as of Q2 2026.
  • Akebia Therapeutics was a new PNC Financial Services Group position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4864 holding.
  • PNC Financial Services Group first reported a position in Akebia Therapeutics in Q4 2017 and has held it in 13 quarters since.
  • PNC Financial Services Group's Akebia Therapeutics position peaked at $2.99M in Q1 2018.
  • 60 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.